Advanced technology for production of foreign proteins in plant cell and organ cultures. The aim of this project is to develop new technology for in vitro production of pharmaceutical proteins using plant tissue culture. Animal proteins such as antibodies are currently being produced using recombinant plant systems in bioreactors; however, transient gene expression using genetically-modified viruses has a range of potential benefits for substantially increasing foreign protein titres. Because vi ....Advanced technology for production of foreign proteins in plant cell and organ cultures. The aim of this project is to develop new technology for in vitro production of pharmaceutical proteins using plant tissue culture. Animal proteins such as antibodies are currently being produced using recombinant plant systems in bioreactors; however, transient gene expression using genetically-modified viruses has a range of potential benefits for substantially increasing foreign protein titres. Because viruses rapidly infect plant tissues and can be amplified to extremely high levels, this new method for in vitro foreign protein synthesis has considerable promise. This project will extend the existing science of plant tissue culture into new areas with commercial potential.Read moreRead less
Benign fabrication of microfluidic hydrogel for improved artificial vasculature in bone implants. We will create a benign technology for synthesising microfluidic hydrogels to generate artificial vascultures in bone implants. It is a critical step to enable the use of tissue-engineered vital organs, such as bone, heart and kidney in patients with end-stage organ failure. Thicker scaffolds will be possible, as the vasculature will provide nutrients and oxygen for cells to grow into 3D scaffolds. ....Benign fabrication of microfluidic hydrogel for improved artificial vasculature in bone implants. We will create a benign technology for synthesising microfluidic hydrogels to generate artificial vascultures in bone implants. It is a critical step to enable the use of tissue-engineered vital organs, such as bone, heart and kidney in patients with end-stage organ failure. Thicker scaffolds will be possible, as the vasculature will provide nutrients and oxygen for cells to grow into 3D scaffolds. It will promote capacity of Australia for manufacturing global biomaterial products for tissue engineering. We will also develop in-situ imaging analytical protocols for the rapid analysis of broad arrays of functional molecules, with significant bearing on BioMEMS design to develop methods for diagnosis of fatal diseases.Read moreRead less